XENON PHARMACEUTICALS

🇮🇳India

Country: 🇮🇳India

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: $3.1B

Website: http://www.xenon-pharma.com/

Clinical Trials

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Phase 3

Recruiting

Conditions: Focal Onset Seizures

Interventions: Drug: XEN1101
Drug: Placebo

First Posted Date: 2023-02-08

Last Posted Date: 2024-11-07

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 360

Registration Number: NCT05716100

Locations: 🇵🇹
Hospital da Senhora da Oliveira, Guimarães, Portugal
🇵🇹
Centro Hospitalar de Lisboa Norte, Lisbon, Portugal
🇵🇹
Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal

and more 55 locations

An Open-label Study of XEN1101 in Epilepsy

Phase 3

Conditions: Focal Epilepsy
Tonic-Clonic Seizures

Interventions: Drug: XEN1101

First Posted Date: 2023-02-08

Last Posted Date: 2024-03-05

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 880

Registration Number: NCT05718817

Locations: 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸
MMP Neurology, Scarborough, Maine, United States
🇺🇸
Northeast Epilepsy Group, Hackensack, New Jersey, United States

and more 15 locations

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Phase 3

Recruiting

Conditions: Primary Generalized Tonic-Clonic Seizures

Interventions: Drug: XEN1101
Drug: Placebo

First Posted Date: 2022-12-28

Last Posted Date: 2024-12-02

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 160

Registration Number: NCT05667142

Locations: 🇺🇸
University California, Davis Clinical & Translation Science Center Clinical Research (CCRC), Sacramento, California, United States
🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States

and more 108 locations

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Phase 3

Recruiting

Conditions: Focal Onset Seizures

Interventions: Drug: XEN1101
Drug: Placebo

First Posted Date: 2022-11-14

Last Posted Date: 2024-11-11

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 360

Registration Number: NCT05614063

Locations: 🇺🇸
Serenity Research, Miami, Florida, United States
🇺🇸
Medstar Health Research Institute, Hyattsville, Maryland, United States
🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia

and more 106 locations

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: XEN1101 10 mg
Drug: Placebo
Drug: XEN1101 20 mg

First Posted Date: 2022-05-17

Last Posted Date: 2024-03-18

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 168

Registration Number: NCT05376150

Locations: 🇺🇸
FutureSearch Trials of Dallas, LP, Dallas, Texas, United States
🇺🇸
Neurobehavioral Research, Inc. (NBR), Cedarhurst, New York, United States
🇺🇸
Manhattan Behavioral Medicine, PLLC, New York, New York, United States

and more 16 locations

Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 14C-XEN1101

First Posted Date: 2021-07-07

Last Posted Date: 2022-01-14

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 6

Registration Number: NCT04952467

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Phase 3

Terminated

Conditions: Nervous System Diseases
Epilepsy in Children
Disease
Central Nervous System Diseases
Epileptic Syndromes
Epilepsy; Seizure
Epilepsy
Brain Diseases

Interventions: Drug: XEN496
Drug: Placebo

First Posted Date: 2021-06-03

Last Posted Date: 2023-12-26

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 8

Registration Number: NCT04912856

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇦🇺
Sydney Children's Hospital, Sydney, New South Wales, Australia
🇧🇪
Universitair Ziekenhuis Antwerpen - Dienst Kinderneurologie, Edegem, Antwerpen, Belgium

and more 1 locations

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Phase 3

Terminated

Conditions: Disease
Epilepsy
Epilepsy in Children
Epilepsy; Seizure
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Epileptic Syndromes

Interventions: Drug: XEN496
Drug: Placebo

First Posted Date: 2020-11-20

Last Posted Date: 2024-08-23

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 8

Registration Number: NCT04639310

Locations: 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Anne & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 17 locations

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Phase 2

Active, not recruiting

Conditions: Focal Epilepsy

Interventions: Drug: XEN1101

First Posted Date: 2019-01-08

Last Posted Date: 2024-04-19

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 325

Registration Number: NCT03796962

Locations: 🇺🇸
James W. Aston Ambulatory Care Center, Dallas, Texas, United States
🇺🇸
Don Clinical Research Center, Miami, Florida, United States
🇺🇸
The Neurology Research Group, LLC., Miami, Florida, United States

and more 91 locations

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: XPF-008
Drug: Microcrystalline Cellulose

First Posted Date: 2018-03-16

Last Posted Date: 2018-09-18

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 20

Registration Number: NCT03468725

Locations: 🇬🇧
King's College Hospital, Brixton, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy